Vaccines (Basel) . Impact of Pre-Existing Immunity to Influenza on Live-Attenuated Influenza Vaccine (LAIV) Immunogenicity

[tetano]

Vaccines (Basel)


. 2020 Nov 16;8(4):E683.
doi: 10.3390/vaccines8040683.
Impact of Pre-Existing Immunity to Influenza on Live-Attenuated Influenza Vaccine (LAIV) Immunogenicity


Sreeja Roy ¹ , Clare M Williams ¹ , Danushka K Wijesundara ² , Yoichi Furuya ¹



Affiliations

• PMID: 33207559
• DOI: 10.3390/vaccines8040683

Free article

Abstract

During the previous influenza seasons, between 2010 and 2016, the live attenuated influenza vaccine (LAIV) provided variable efficacy against influenza in the U.S., causing the recommendation against the use of the LAIV. In striking contrast, pre-clinical studies have repeatedly demonstrated superior efficacy of LAIV against mismatched influenza viruses, compared to inactivated influenza vaccines (IIV). This disparity in reported vaccine efficacies between pre-clinical and clinical studies may in part be explained by limitations of the animal models of influenza. In particular, the absence of pre-existing immunity in animal models has recently emerged as a potential explanation for the discrepancies between preclinical findings and human studies. This commentary focuses on the potential impact of pre-existing immunity on LAIV induced immunogenicity with an emphasis on cross-protective immunity.

Keywords: T cell immunogenicity; live attenuated influenza vaccine; mucosal responses; pre-existing antibodies; pre-existing immunity.